CN111921046B - 经鼻给药 - Google Patents

经鼻给药 Download PDF

Info

Publication number
CN111921046B
CN111921046B CN202010816000.4A CN202010816000A CN111921046B CN 111921046 B CN111921046 B CN 111921046B CN 202010816000 A CN202010816000 A CN 202010816000A CN 111921046 B CN111921046 B CN 111921046B
Authority
CN
China
Prior art keywords
nosepiece
nasal
projection
length
oxytocin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010816000.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN111921046A (zh
Inventor
柏·吉斯勒·尤佩斯兰
柯林·戴维·谢尔德雷克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptinos Co ltd
Original Assignee
Optinose AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optinose AS filed Critical Optinose AS
Publication of CN111921046A publication Critical patent/CN111921046A/zh
Application granted granted Critical
Publication of CN111921046B publication Critical patent/CN111921046B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A61M15/0098—Activated by exhalation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M29/00—Dilators with or without means for introducing media, e.g. remedies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0618—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
CN202010816000.4A 2014-11-19 2015-11-19 经鼻给药 Active CN111921046B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462081742P 2014-11-19 2014-11-19
US62/081,742 2014-11-19
PCT/EP2015/077166 WO2016079271A1 (en) 2014-11-19 2015-11-19 Intranasal administration
CN201580062178.1A CN107106792B (zh) 2014-11-19 2015-11-19 经鼻给药

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580062178.1A Division CN107106792B (zh) 2014-11-19 2015-11-19 经鼻给药

Publications (2)

Publication Number Publication Date
CN111921046A CN111921046A (zh) 2020-11-13
CN111921046B true CN111921046B (zh) 2022-07-22

Family

ID=54695714

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202010816000.4A Active CN111921046B (zh) 2014-11-19 2015-11-19 经鼻给药
CN201580062178.1A Active CN107106792B (zh) 2014-11-19 2015-11-19 经鼻给药
CN201580062083.XA Active CN106999684B (zh) 2014-11-19 2015-11-19 经鼻给药

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201580062178.1A Active CN107106792B (zh) 2014-11-19 2015-11-19 经鼻给药
CN201580062083.XA Active CN106999684B (zh) 2014-11-19 2015-11-19 经鼻给药

Country Status (19)

Country Link
US (6) US11052204B2 (enExample)
EP (3) EP3733235B1 (enExample)
JP (2) JP6990583B2 (enExample)
KR (2) KR20170086599A (enExample)
CN (3) CN111921046B (enExample)
AU (2) AU2015348297A1 (enExample)
BR (2) BR112017010522B1 (enExample)
CA (2) CA2966802C (enExample)
DK (2) DK3220988T3 (enExample)
ES (3) ES2906984T3 (enExample)
HK (1) HK1244729A1 (enExample)
IL (2) IL251935A0 (enExample)
MX (2) MX2017006265A (enExample)
MY (1) MY188242A (enExample)
PL (1) PL3220989T3 (enExample)
RU (2) RU2714168C2 (enExample)
SG (2) SG11201703792XA (enExample)
WO (2) WO2016079271A1 (enExample)
ZA (1) ZA201704149B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0311570D0 (en) 2003-05-20 2003-06-25 Optinose As Delivery device and method
GB0320171D0 (en) 2003-08-28 2003-10-01 Optinose As Delivery devices
GB0420513D0 (en) 2004-09-15 2004-10-20 Optinose As Powder delivery devices
GB0503738D0 (en) 2005-02-23 2005-03-30 Optinose As Powder delivery devices
GB0604444D0 (en) * 2006-03-06 2006-04-12 Optinose As Nasal devices
GB0605799D0 (en) 2006-03-23 2006-05-03 Optinose As Nasal delivery devices
GB2438834A (en) 2006-06-08 2007-12-12 Optinose As Intranasal protein administration
GB2440316A (en) 2006-07-25 2008-01-30 Optinose As Nasal inhaler with scrubber
GB0623731D0 (en) 2006-11-28 2007-01-10 Optinose As Delivery device
GB0623732D0 (en) 2006-11-28 2007-01-10 Optinose As Powder delivery devices
GB0623728D0 (en) 2006-11-28 2007-01-10 Optinose As Delivery devices
GB2448193A (en) 2007-04-05 2008-10-08 Optinose As Nasal delivery device
GB2448183A (en) 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
GB0719299D0 (en) 2007-10-03 2007-11-14 Optinose As Nasal delivery devices
US9949923B2 (en) 2011-03-15 2018-04-24 Optinose As Nasal delivery
SG10201600092UA (en) 2012-02-24 2016-02-26 Optinose As Nasal Delivery Devices
USD761951S1 (en) 2013-05-23 2016-07-19 Optinose As Nosepiece unit
JP6990583B2 (ja) 2014-11-19 2022-01-12 オプティノーズ アズ 鼻腔内投与
US10368502B2 (en) 2017-09-25 2019-08-06 Multiple Energy Technologies Llc Bioceramic and carbon-based hydroponic systems, methods and devices
JP2021520266A (ja) 2018-04-12 2021-08-19 ロケット サイエンス ヘルス コープ． 鼻腔内薬剤送達デバイス、システム、およびプロセス
KR102148613B1 (ko) * 2019-01-28 2020-10-14 닉스 주식회사 이산화탄소를 이용한 수면 유도시스템
CN110188836B (zh) * 2019-06-21 2021-06-11 西安交通大学 一种基于变分自编码器的脑功能网络分类方法
US20220313895A1 (en) * 2019-08-14 2022-10-06 Gsk Consumer Healthcare Sarl Bi-material nozzle for nasal washes
US11241477B2 (en) 2019-08-29 2022-02-08 New York University Oxytocin compositions for treatment of tinnitus
US20220161000A1 (en) * 2020-11-24 2022-05-26 Medtronic, Inc. Multi-durometer attachment device for chronic fixation
CN112972879A (zh) * 2021-04-20 2021-06-18 苏州新劢德医疗器械科技有限公司 流体分配设备
CN112999499A (zh) * 2021-04-20 2021-06-22 苏州新劢德医疗器械科技有限公司 流体分配设备
CN114306207A (zh) * 2021-12-30 2022-04-12 电子科技大学 一种以棒棒糖为载体的口腔给药方法
US20230285278A1 (en) * 2022-03-06 2023-09-14 Optinose, Inc. Methods for treating chronic rhinosinusitis
WO2025118074A1 (en) * 2023-12-04 2025-06-12 Rocket Science Health Corp. Olfactory delivery of therapeutic peptides
WO2025174892A1 (en) * 2024-02-13 2025-08-21 Breathewave Technologies Inc. Personalized-fit nasal dilator

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1280512A (zh) * 1997-11-25 2001-01-17 雷克斯姆Sofab股份公司 带有封闭膜的喷鼻装置
WO2005016423A2 (en) * 2003-08-14 2005-02-24 Optinose As Delivery devices
CN101723143A (zh) * 2004-03-11 2010-06-09 葛兰素集团有限公司 流体分配装置
CN101918061A (zh) * 2007-10-03 2010-12-15 奥普蒂诺斯公司 鼻腔递送装置
CN103237570A (zh) * 2010-12-06 2013-08-07 利肯萨实验室股份有限公司 吸入器
WO2013124491A1 (en) * 2012-02-24 2013-08-29 Optinose As Nasal delivery devices
WO2014155192A2 (en) * 2013-03-26 2014-10-02 Optinose As Nasal administration

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US605436A (en) 1898-06-07 Inhaler
US642748A (en) 1899-02-23 1900-02-06 Arthur Manners Inhaler.
US658436A (en) 1900-05-28 1900-09-25 Hans Hennerich Groth Insufflator.
US746749A (en) 1903-03-18 1903-12-15 George E Seidel Nasal medicator.
US794641A (en) 1905-03-06 1905-07-11 Alfred H Ramey Inhaler.
US902832A (en) 1907-09-20 1908-11-03 Edward F Philbrook Inhaler.
KR100390480B1 (ko) 1995-01-23 2003-10-04 디렉트-할러 아/에스 흡입기
US5901703A (en) 1995-02-06 1999-05-11 Unisia Jecs Corporation Medicine administering device for nasal cavities
JP3320288B2 (ja) * 1995-11-15 2002-09-03 株式会社ユニシアジェックス 鼻腔用投薬器
US5797392C1 (en) 1996-01-22 2001-01-09 Direct Haler As Inhaler
US6648848B1 (en) 1997-05-27 2003-11-18 Direct-Haler A/S Inhaler for powdered medicaments
GB9719775D0 (en) 1997-09-18 1997-11-19 Glaxo Group Ltd Device
GB0114272D0 (en) 2001-06-12 2001-08-01 Optinose As Nasal delivery device
BR0008650B1 (pt) 1999-03-03 2010-12-28 dispositivo de transmissão via nasal.
GB0121568D0 (en) 2001-09-06 2001-10-24 Optinose As Nasal delivery device
US20070032410A1 (en) 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
US6894026B1 (en) 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
GB0015309D0 (en) 2000-06-21 2000-08-16 Djupesland Per G Apparatus
ZA200306564B (en) 2001-02-26 2004-10-15 Optinose As Nasal devices.
GB0207422D0 (en) 2002-03-28 2002-05-08 Optinose As Nasal devices
GB0207817D0 (en) 2002-04-04 2002-05-15 Optinose As Nasal devices
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
GB0215270D0 (en) 2002-07-02 2002-08-14 Optinose As Nasal devices
GB0215904D0 (en) 2002-07-09 2002-08-21 Team Holdings Uk Ltd Drug delivery system and method
GB0300008D0 (en) 2003-01-02 2003-02-05 Optinose As Delivery devices
GB2400565B (en) 2003-04-17 2005-03-02 Bespak Plc Nasal drug delivery
GB0311570D0 (en) 2003-05-20 2003-06-25 Optinose As Delivery device and method
GB0320171D0 (en) 2003-08-28 2003-10-01 Optinose As Delivery devices
USD530815S1 (en) 2004-03-19 2006-10-24 Optinose As Nasal delivery device
GB0420513D0 (en) 2004-09-15 2004-10-20 Optinose As Powder delivery devices
GB0503738D0 (en) 2005-02-23 2005-03-30 Optinose As Powder delivery devices
EP1928484B1 (en) 2005-08-26 2010-02-24 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
JP4765526B2 (ja) 2005-10-04 2011-09-07 オムロンヘルスケア株式会社 吸入器および吸入器用マウスピース
EP1984049A1 (en) 2006-01-19 2008-10-29 Optinose AS Nasal administration
EP1988953B1 (en) 2006-02-14 2017-07-19 Optinose AS Delivery device
GB0602980D0 (en) 2006-02-14 2006-03-29 Optinose As Delivery device and method
GB0604319D0 (en) 2006-03-03 2006-04-12 Optinose As Nasal delivery
GB0604444D0 (en) * 2006-03-06 2006-04-12 Optinose As Nasal devices
GB0605799D0 (en) 2006-03-23 2006-05-03 Optinose As Nasal delivery devices
GB2437488A (en) 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB2438834A (en) 2006-06-08 2007-12-12 Optinose As Intranasal protein administration
GB2440316A (en) 2006-07-25 2008-01-30 Optinose As Nasal inhaler with scrubber
JP2008062974A (ja) * 2006-09-07 2008-03-21 Mitani Valve Co Ltd 内容物放出用容器ならびに、この内容物放出用容器を備えたポンプ式製品およびエアゾール式製品
GB0623731D0 (en) 2006-11-28 2007-01-10 Optinose As Delivery device
GB0623728D0 (en) 2006-11-28 2007-01-10 Optinose As Delivery devices
GB0623732D0 (en) 2006-11-28 2007-01-10 Optinose As Powder delivery devices
US20100199984A1 (en) 2007-04-02 2010-08-12 Abbott Laboratories Breath actuated nasal pump
GB2448193A (en) * 2007-04-05 2008-10-08 Optinose As Nasal delivery device
GB2448183A (en) 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
US8342173B2 (en) 2007-07-19 2013-01-01 Silver Eagle Labs Inc. Nasal dilator with cushion layer and variable spring rate
EP3272379A1 (en) 2008-02-07 2018-01-24 The University of Washington Circumferential aerosol device
EP2242526A4 (en) 2008-02-15 2014-06-18 Timothy Sean Immel AEROSOL TREATMENT DEVICE WITH HIGH FREQUENCY ADMINISTRATION
US20110318345A1 (en) 2008-09-15 2011-12-29 Optinose As Nasal delivery
GB201015371D0 (en) 2010-09-14 2010-10-27 Optinose As Nasal delivery
US9949923B2 (en) 2011-03-15 2018-04-24 Optinose As Nasal delivery
RU112044U1 (ru) * 2011-08-25 2012-01-10 Наиль Минрахманович Нуртдинов Тренажер-ингалятор
JP6382723B2 (ja) 2012-02-24 2018-08-29 オプティノーズ アズ 経鼻配送装置
JP6286367B2 (ja) 2012-02-24 2018-02-28 オプティノーズ アズ 経鼻配送装置
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
USD761951S1 (en) 2013-05-23 2016-07-19 Optinose As Nosepiece unit
USD725769S1 (en) 2013-05-23 2015-03-31 Optinose As Nasal delivery device
USD723156S1 (en) 2013-05-23 2015-02-24 Optinose As Nasal delivery device
JP6990583B2 (ja) 2014-11-19 2022-01-12 オプティノーズ アズ 鼻腔内投与
US20220296825A1 (en) 2018-10-04 2022-09-22 Optinose As Exhalation delivery system for and method of treating sinus disease

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1280512A (zh) * 1997-11-25 2001-01-17 雷克斯姆Sofab股份公司 带有封闭膜的喷鼻装置
WO2005016423A2 (en) * 2003-08-14 2005-02-24 Optinose As Delivery devices
CN101723143A (zh) * 2004-03-11 2010-06-09 葛兰素集团有限公司 流体分配装置
CN101918061A (zh) * 2007-10-03 2010-12-15 奥普蒂诺斯公司 鼻腔递送装置
CN103237570A (zh) * 2010-12-06 2013-08-07 利肯萨实验室股份有限公司 吸入器
WO2013124491A1 (en) * 2012-02-24 2013-08-29 Optinose As Nasal delivery devices
WO2014155192A2 (en) * 2013-03-26 2014-10-02 Optinose As Nasal administration

Also Published As

Publication number Publication date
CA2966797A1 (en) 2016-05-26
AU2015348297A1 (en) 2017-05-25
US11707586B2 (en) 2023-07-25
MY188242A (en) 2021-11-24
CA2966797C (en) 2023-06-27
ES2949052T3 (es) 2023-09-25
JP2017538477A (ja) 2017-12-28
US20210322690A1 (en) 2021-10-21
HK1244729A1 (zh) 2018-08-17
DK3220988T3 (da) 2022-02-14
US20250114543A1 (en) 2025-04-10
WO2016079267A1 (en) 2016-05-26
BR112017010522B1 (pt) 2022-08-02
AU2015348301B2 (en) 2020-09-03
US20160331916A1 (en) 2016-11-17
CN107106792A (zh) 2017-08-29
CN111921046A (zh) 2020-11-13
US20160310683A1 (en) 2016-10-27
IL251935A0 (en) 2017-06-29
EP3220989A1 (en) 2017-09-27
JP6937690B2 (ja) 2021-09-22
ES2906984T3 (es) 2022-04-21
CN106999684A (zh) 2017-08-01
US20210275761A1 (en) 2021-09-09
EP3733235C0 (en) 2023-06-14
SG11201703792XA (en) 2017-06-29
EP3220989B1 (en) 2020-06-24
KR20170086599A (ko) 2017-07-26
PL3220989T3 (pl) 2021-03-22
EP3220988B1 (en) 2022-01-12
MX2017006265A (es) 2017-08-14
JP6990583B2 (ja) 2022-01-12
MX2017006268A (es) 2017-08-14
CN107106792B (zh) 2020-08-18
RU2714168C2 (ru) 2020-02-12
EP3733235A1 (en) 2020-11-04
RU2017114951A3 (enExample) 2019-04-16
IL251936A0 (en) 2017-06-29
WO2016079271A1 (en) 2016-05-26
EP3220988A1 (en) 2017-09-27
KR20170085121A (ko) 2017-07-21
BR112017010561A2 (pt) 2017-12-26
IL251936B (en) 2020-07-30
US20230372647A1 (en) 2023-11-23
ZA201704149B (en) 2019-12-18
US11052204B2 (en) 2021-07-06
SG11201703794TA (en) 2017-06-29
EP3733235B1 (en) 2023-06-14
CA2966802C (en) 2022-11-15
BR112017010522A2 (pt) 2017-12-26
DK3220989T3 (da) 2020-08-24
JP2017538478A (ja) 2017-12-28
US11730904B2 (en) 2023-08-22
AU2015348301A1 (en) 2017-05-25
RU2017114951A (ru) 2018-12-19
CA2966802A1 (en) 2016-05-26
MX383241B (es) 2025-03-13
ES2813442T3 (es) 2021-03-23
CN106999684B (zh) 2021-03-09
HK1244728A1 (en) 2018-08-17
US10940277B2 (en) 2021-03-09
RU2017114950A (ru) 2018-12-19

Similar Documents

Publication Publication Date Title
CN111921046B (zh) 经鼻给药
Quintana et al. Low dose intranasal oxytocin delivered with Breath Powered device dampens amygdala response to emotional stimuli: A peripheral effect-controlled within-subjects randomized dose-response fMRI trial
HK40033122A (en) Intranasal administration
HK1244728B (en) Intranasal administration
Abdulraouf Almarzooqi et al. Skin Deep: An Overlap of Delusions
Abdulraouf et al. Skin Deep: An Overlap of Delusions
Sorcha et al. Study Protocol for ‘PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity’
Li et al. Foot massage evokes oxytocin release and activation of

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20221028

Address after: Pennsylvania, America

Patentee after: Aptinos Co.,Ltd.

Address before: Oslo, Norway

Patentee before: OptiNose A/S

TR01 Transfer of patent right